Maravai expects 2024 revenue near midpoint of $255M-$265M; President of Nucleic Acid Production departs

MARAVAI LIFESCIENCES HOLDINGS, INC.

Preliminary unaudited 2024 revenue expected near midpoint of $255M-$265M guidance range.
Andrew Burch, President of Nucleic Acid Production, position eliminated; last day Jan 16, 2025.
CEO Trey Martin will assume direct responsibility for Nucleic Acid Production segment.
Q4 and full year 2024 earnings release scheduled for Feb 25, 2025 after market close.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew Burch

President, Nucleic Acid Production

MRVI · MARAVAI LIFESCIENCES HOLDINGS, INC.

Effective: 2025-01-16
Filed: January 8, 2025, 6:59 PM ET

On January 2, 2025, the Company notified Andrew Burch, President, Nucleic Acid Production, that it was eliminating his position in order to flatten the organizational structure of its leadership team. As a result, Mr. Burch’s last day of employment with the Company will be January 16, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Burch departed as President, Nucleic Acid Production at MARAVAI LIFESCIENCES HOLDINGS, INC..

Action: departed
Role: President, Nucleic Acid Production

Exact text from the filing

On January 2, 2025, the Company notified Andrew Burch, President, Nucleic Acid Production, that it was eliminating his position in order to flatten the organizational structure of its leadership team. As a result, Mr. Burch’s last day of employment with the Company will be January 16, 2025.

View on SEC.gov

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-25-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.